(Sharecast News) - Crism Therapeutics reported positive preclinical results for its Docetaxel-ChemoSeed implant on Tuesday, highlighting improved efficacy and tolerability compared with standard chemotherapy in a prostate cancer model.
The AIM-traded clinical-stage group said its implantable drug delivery technology demonstrated significant anti-tumour activity, a clear dose-response relationship and a favourable tolerability...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE